By MEGGLE Excipients…
To get in touch with MEGGLE brings further DPI Inhalation Insights to Mumbai, simply fill out the form below.
Subscribe to Supplier
MEGGLE brings further DPI Inhalation Insights to Mumbai
Wasserburg, Germany: – Pharmaceutical lactose specialist MEGGLE Excipients &Technology (MEGGLE) is following up its presence at the Inhalation Insights symposium in Abu Dhabi with a further appearance at a sister symposium in Mumbai, India.
MEGGLE will again be a prominent contributor to the one-day event with Head of R&D Dr. Mirjam Kobler delivering a presentation on ‘Lactose in Dry Powder Inhaler Formulations’.
InhaLac® DPI range
The MEGGLE table top display in the exhibition zone at the Taj Lands End Hotel in Mumbai will feature its InhaLac® portfolio of excipients specifically formulated for DPI applications.
Inhalation Insights is series of Dry Powder Inhalation Technology Symposiums that have been taking place since 2017, co-organised and sponsored by MEGGLE and Harro Höfliger in association with other leading names from the industry.
DPI value chain
The events are targeted at pharma industry professionals with involvement in DPI technology, sharing first-hand insights and knowledge covering the entire process cycle and value chain.
The Mumbai symposium on September 25 follows an earlier one in Abu Dhabi, UAE, on September 15.
The Mumbai symposium is still accepting registration requests (see Resources).
About MEGGLE Wasserburg
Bavarian-based MEGGLE Wasserburg is one of the world’s experts in lactose-based excipients and powder technology.
From its roots as a dairy operation in the late 1880s, MEGGLE has become one of the world’s leading manufacturers of pharmaceutical lactose, supplying the pharma market segment with a broad-based and unique lactose product portfolio.
MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.
A multidisciplinary team of committed and highly qualified people allows MEGGLE clients to benefit from pioneering experience and innovative drive in industrial milk and whey processing. The company constantly strives to develop high-tech, functional products for solid dosage forms and DPI applications, where they can deliver maximum performance.
The company has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first direct compression co-processed excipient using a hypromellose-lactose base for modified sustained release and controlled release formulations.
About Inhalation Insights
The Inhalation Insights series of symposia are designed to share state of the art views and trends related to dry powder inhaler (DPI) technology for international audiences.
The 2019 program comprises two one-day events are scheduled for the Aloft Abu Dhabi Hotel (September 15) and the Taj Lands End Hotel in Mumbai (September 25).
Both English-language conferences will feature latest innovations in device, excipient and manufacturing technology along the entire value chain of DPI applications from powder characteristics and formulations to device assembly and packaging.
The events also emphasize networking and partnering opportunities.
Inhalation Insights is organised by MEGGLE and Harro Höfliger in partnership with Constantia Flexibles, Copley Scientific, H&T Presspart, Intertek, Merxin and Nanopharm. Further information at: